Baseline demographic and clinical characteristics of the high-risk SMM patient population with available samples for immune profiling at baseline and after 3 and 9 cycles of LenDex
| Characteristic . | High-risk SMM patients (n = 31) . |
|---|---|
| Age, y | |
| Median | 59 |
| Range | 39-87 |
| Sex, n (%) | |
| Male | 14 (45) |
| Female | 17 (55) |
| Time since diagnosis, n (%) | |
| ≤6 mo | 13 (42) |
| >6 mo | 18 (58) |
| Criteria for high-risk SMM, n (%) | |
| Mayo | 6 (19) |
| PETHEMA | 12 (37) |
| Both criteria | 14 (44) |
| Serum M-component, g/dL | |
| Median | 27 |
| Range | 7.6-56.6 |
| Urine M-component, g/24 h | |
| Median | 0 |
| Range | 0-1.5 |
| BM PC infiltration, % | |
| Median | 19 |
| Range | 10-48 |
| Characteristic . | High-risk SMM patients (n = 31) . |
|---|---|
| Age, y | |
| Median | 59 |
| Range | 39-87 |
| Sex, n (%) | |
| Male | 14 (45) |
| Female | 17 (55) |
| Time since diagnosis, n (%) | |
| ≤6 mo | 13 (42) |
| >6 mo | 18 (58) |
| Criteria for high-risk SMM, n (%) | |
| Mayo | 6 (19) |
| PETHEMA | 12 (37) |
| Both criteria | 14 (44) |
| Serum M-component, g/dL | |
| Median | 27 |
| Range | 7.6-56.6 |
| Urine M-component, g/24 h | |
| Median | 0 |
| Range | 0-1.5 |
| BM PC infiltration, % | |
| Median | 19 |
| Range | 10-48 |
PETHEMA, Programa de Estudio y Tratamiento de las Hemopatías Maligna.